Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 56, Issue 6, 1996, Pages 563-570

  Alvarsson, M ^a   Grill, V ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

insulin secretion; insulin sensitivity; nicotinic acid; non esterified fatty acids

Indexed keywords

FATTY ACID; INSULIN; NICOTINIC ACID;

ADULT; ARTICLE; FEMALE; HUMAN; HUMAN EXPERIMENT; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029805774     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365519609088812     Document Type: Article

References (29)

1. Cerasi E, Luft R. The plasma insulin response to glucose infusion in healthy subjects and in diabetes mellitus. Acta Endocrinol (Copenh) 1967; 55: 278-304.
2. Alvarsson M, Grill VE, Wajngot A, Cerasi E, Efendic S. Long-term stability of low insulin responses in non-diabetic subjects. Acta Endocrinol (Copenh) 1992; 127: 33-7.
3. Lindsten J, Cerasi E, Luft R, Morton N, Ryman N. Significance of genetic factors for the plasma insulin response to glucose in healthy subjects. Clin Genet 1976; 10: 125-34.
4. Iselius L, Lindsten J, Morton NE, Efendic S, Cerasi E, Haegermark A, et al. Evidence of an autosomal recessive gene regulating the persistence of the insulin response to glucose in man. Clin Genet 1982; 22: 180-94.
5. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, et al. Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes 1993; 42: 1663-72.
6. Beard JC, Halter JB, Best JD, Pfeifer MA, Porte D Jr. Dexamethasone-induced insulin resistance enhances B cell responsiveness to glucose level in normal men. Am J Physiol 1984; 247: E592-6.
7. Grill V, Pigon J, Hartling SC, Binder C, Efendic S. Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high insulin responders. Metabolism 1990; 39: 251-8.
8. Grill V, Alvarsson M, Efendic S. Dexamethasone treatment fails to increase arginine-induced insulin release in healthy subjects with low insulin response. Diabetologia 1992; 35: 367-71.
9. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405-18.
10. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. for the Coronary Drug Project Research Group. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55.
11. Miettinen TA, Taskinen M-R, Pelkonen R, Nikkilä EA. Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. Acta Med Scand 1969; 186: 247-53.
12. McCulloch DK, Kahn SE, Schwartz MW, Koerker DJ, Palmer JP. Effect of nicotinic acid-induced insulin resistance on pancreatic B-cell function in normal and streptozocin-treated baboons. J Clin Invest 1991; 87: 1395-401.
13. Kahn SE, McCulloch DK, Schwartz MW, Palmer JP, Porte D Jr. Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus. J Clin Endocrinol Metab 1992; 74: 192-7.
14. Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, et al. Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 1989; 38: 562-8.
15. Herbert V, Lau KS, Gottlieb CW, Bleicher SJ. Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 1965; 25: 1375-84.
16. Faloona GR, Unger RH. Glucagon radioimmuno-assay technique. In: Jaffe BM, Behrman HE, edi-tors. Methods of hormone radioimmunoassay. New York: Academic Press, 1974; 317-30.
17. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-23.
18. Mitrakou A, Vuorinen-Markkola H, Raptis G, Toft I, Mokan M, Strumph P, et al. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemic clamp. J Clin Endocrinol Metab 1992; 75: 379-82.
19. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr. Diminished B-cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 1984; 74: 1318-28.
20. Berge KG. Side effects of nicotinic acid in treatment of hypercholesteremia. Geriatrics 1961; 416-22.
21. Gaut ZN, Solomon HM, Miller ON. The influence of antilipemic doses of nicotinic acid on carbohydrate tolerance and plasma insulin levels in man. In: Gey KF, Carlson LA, editors. Metabolic effects of nicotinic acid and its derivatives. Berne: Hans Huber, 1971: 923-7.
22. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. J Am Med Assoc 1990; 264: 723-6.
23. Löffler G, Trautschold I. Influence of nicotinic acid on insulin secretion in vivo and in vitro. In: Gey KF, Carlson LA, editors. Metabolic effects of nicotinic acid and its derivates. Berne: Hans Huber, 1971: 933-7.
24. Bevilacqua S, Bonadonna R, Buzzigoli G, Boni C, Ciociaro D, Maccari F, et al. Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metabolism 1987; 36: 502-6.
25. Bonadonna RC, Zych K, Boni C, Ferrannini E, DeFronzo RA. Time dependence of the interaction between lipid and glucose in humans. Am J Physiol 1989; 257: E49-56.
26. Boden G, Jadali F. Effects of lipid on basal carbohydrate metabolism in normal men. Diabetes 1991; 40: 686-92.
27. Nikkilä EA, Miettinen TA. Nicotinic acid and gluconeogenesis in man. In: Gey KF, Carlson LA, editors. Metabolic effects of nicotinic acid and its derivatives. Berne: Hans Huber, 1971: 753-5.
28. Fulcher GR, Walker M, Catalano C, Agius L, Alberti KGMM. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects. Diabetes 1992; 41: 1400-8.
29. Saloranta C, Taskinen MR, Widen E, Härkönen M, Melander A, Groop L. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM. Diabetes 1993; 42: 1559-66.